PRC
MDGL icon

Pearl River Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Pearl River Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-758
Closed -$94K – 405
2019
Q1 		$94K Buy
758
+505
+200% +$62.8K 0.23% 179
2018
Q4 		$29K Buy
+253
New +$39.2K 0.13% 200

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pearl River Capital's MDGL Position: Q2 2019 in Review

Pearl River Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2019, closing a stake of 758 shares — an estimated $94K sold.

Pearl River Capital first reported a position in MDGL in Q4 2018 and held it in 2 quarters. The position peaked at $94K in Q1 2019. 116 funds tracked by Wall St. Rank hold MDGL as of Q2 2019.

  • Pearl River Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Pearl River Capital sold 758 Madrigal Pharmaceuticals shares in Q2 2019, an estimated $94K.
  • Pearl River Capital first reported a position in Madrigal Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's Madrigal Pharmaceuticals position peaked at $94K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.